Organization
Celgene Corporation, Summit, United States of America
5 abstracts
Abstract
A SYSTEMATIC LITERATURE REVIEW OF HEALTHCARE BURDEN IN PATIENTS WITH BEHÇET’S DISEASEOrg: Health Institute for Technology Transfer (HITT), Barcelona, Spain, Celgene Corporation, Summit, United States of America, Pharmerit International, LP, Bethesda, United States of America, Pharmerit International, Bethesda, United States of America, San Carlo Hospital of Potenza, Rheumatology Department of Lucania, Potenza, Italy,
Abstract
ASSESSMENT OF DISABILITY LEVELS IN A COHORT OF 1,489 PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS, AND THE EFFECT OF APREMILAST TREATMENT: POOLED DATA FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, Schön Klinik Hamburg Eilbek, Hamburg, Germany, Monash University, CabriniHealth, Melbourne, Australia, UZ Gent, Gent, Belgium, University of Orléans, Orléans, France,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN BASDAI IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, UZ Gent, Gent, Belgium, Schön Klinik Hamburg Eilbek, Hamburg, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (156-WEEK) IMPROVEMENTS IN BASDAI IN PSORIATIC ARTHRITIS PATIENTS: POOLED RESULTS FROM 3 PHASE III, RANDOMIZED, CONTROLLED TRIALS Org: Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals and University of Leeds, Leeds, United Kingdom, Clinical Research Centre Ltd, Tartu, Estonia, UZ Gent, Gent, Belgium, Schön Klinik Hamburg Eilbek, Hamburg, Germany,
Abstract
B-CELL PROLIFERATION AND PLASMABLAST GENERATION FROM NAIVE AND MEMORY B CELLS ARE DIFFERENTIALLY REGULATED BY BAFF, IL-21, AND CD40L AND INHIBITED BY THE SYSTEMIC LUPUS ERYTHEMATOSUS DRUG CANDIDATE CC-220 Org: Celgene Corporation, Summit, United States of America,